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humanistic and economic burden on patients, and there are 
still unmet needs across key domains such as pain, physical 
function, mental function, and fatigue. These findings sug-
gest that there is a need for further treatment advances in RA 
that address these domains of contemporary unmet need.
Keywords Cost · Fatigue · Mental functioning · Pain · 
Physical functioning · Rheumatoid arthritis
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease characterized by pain and stiffness of affected joints, 
with an estimated global prevalence of 0.3–1.0 % [1]. 
Fatigue, joint inflammation, and deformities are key com-
plications of RA leading to impaired physical functioning, 
work productivity, and activities of daily living, which can 
also compromise overall emotional well-being [2]. Sub-
optimal treatment can exacerbate this decline, causing a 
considerable burden to patients and a substantial strain on 
global healthcare resources [3, 4].
In the contemporary treatment paradigm, methotrex-
ate (MTX)—a conventional synthetic disease-modifying 
antirheumatic drug (csDMARD)—is the recommended 
first-line treatment for patients with RA, often adminis-
tered in combination with other csDMARDs. In patients 
with an inadequate response to first-line csDMARDs, MTX 
is generally used in combination with a concomitant bio-
logic DMARD (bDMARD) such as a tumor necrosis factor 
(TNF) inhibitor [5, 6].
Although the achievable outcomes for RA continue to 
evolve and improve, not all patients are able to attain the 
desirable treatment goal of remission or, failing that, of low 
disease activity (LDA). While the emphasis of rheumatology 
Abstract While rheumatologists often focus on treatment 
targets, for many patients with rheumatoid arthritis (RA), 
control over pain and fatigue, as well as sustaining physi-
cal function and quality of life (QoL), is of primary impor-
tance. This literature review aimed at examining patients’ 
and physicians’ treatment aspirations, and identifying the 
unmet needs for patients with RA receiving ongoing treat-
ment. Searches were performed using MEDLINE, Embase, 
PsycINFO, and Econlit literature databases for articles pub-
lished from 2004 to 2014 in the English language. Published 
literature was screened to identify articles reporting the 
unmet needs in RA. We found that, despite the wide range 
of available treatments, RA continues to pose a substantial 
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care has been on attainment of these treatment targets, for 
many patients, particularly those in whom these targets 
are not achieved, control over symptoms such as pain and 
fatigue, as well as maintaining physical function and quality 
of life (QoL), is of primary importance. Therefore, mitigat-
ing the negative impact of the disease on patients’ lives and 
QoL, reducing or halting disability, and achieving clinical 
remission continue to be a focus of research [7–10].
The primary objectives of this literature review were to 
identify and summarize the unmet needs of patients with 
RA despite receiving ongoing treatment with csDMARDs 
with or without concomitant biologic therapies.
The secondary objectives were to investigate the human-
istic and economic burden of RA, the potential discordance 
between patients’ treatment goals and perceptions of well-
being, and physicians’ therapeutic targets based primarily 
upon disease activity assessments.
Patients and methods
Assessment of unmet medical needs in RA: literature 
search and review methodology
Searches were conducted in March 2014 using MEDLINE, 
Embase, PsycINFO, and Econlit literature databases and 
limited to human studies published in English from Janu-
ary 2004 to March 2014. Published literature was screened 
using search terms combined with subsearches to identify 
articles reporting the burden of RA in patients receiving 
ongoing treatment (Table 1).
Two levels of core search terms were included: One 
related to the condition of study, and the second used treat-
ment-related search terms. Articles that included terms from 
both of these levels were identified by two researchers. 
Search terms related to treatments were included as a key 
objective of the search. Following the exclusion of dupli-
cate articles across the humanistic and economic burden 
subsearches, articles were identified for inclusion. Titles of 
articles were screened to exclude any articles that could be 
deemed irrelevant; articles and abstracts were screened and 
excluded if relevant terms were included as background, as 
an implication in the discussion, or were lacking in data. All 
conference abstracts were excluded from this review.
Key outcome measures included aspects of life impor-
tant to patients such as pain, physical functioning, mental 
functioning, fatigue, social functioning, sexual function-
ing, and treatment-related issues, as well as impact on work 
and economic burden. Minimal clinically important differ-
ence (MCID) values were utilized when available to assess 
the magnitude of changes over time. In addition, patient 
acceptable symptom state (PASS) values were used when 
available to determine whether the observed values would 
be acceptable to patients with RA (Table 2).
Results
The search identified 3212 unique articles; 1688 were 
excluded as it was clear from their title that they were irrel-
evant to the goals of the study, or that RA was not the focus 
of the article. Of the remaining 1524 articles, 1447 were 
removed at the abstract screening stage. In total, the search 
identified 77 key publications that reported on the human-
istic (68 articles) and economic burden (9 articles) of RA.
Pain
In total, 13 articles (comprising 14 cohorts) were identi-
fied that discussed the impact of pain in patients with RA, in 
Table 1  Core search terms and subsearches
DMARD disease-modifying antirheumatic drug, HRQoL health-related quality of life, QoL quality of life, RA rheumatoid arthritis
Evidence requirement Search terms
Condition (required to be in title) Rheumatoid arthritis OR RA
AND




Quality of life OR QoL OR health-related quality of life OR HRQL OR HRQoL OR activities of daily 
living OR hobbies OR physical functioning OR social impact OR emotional impact OR social interaction 
OR isolation OR physical ability OR mental function OR psychological function OR work disability OR 
sexual function OR pain OR stiffness OR stiff OR loss of strength OR loss of movement OR fatigue OR 
joint function OR swollen joint$ OR swelling OR patient preference OR needle phobia OR adverse events 
OR side effects OR adherence OR treatment discontinuation OR treatment burden OR patient impact OR 
burden of illness OR treatment convenience OR treatment administration OR treatment preparation OR 
dosing schedule OR treatment frequency
Subsearch 2
Economic burden
Cost of illness OR healthcare cost OR economic burden OR economic impact OR resource use OR hospi-
talization OR productivity OR expenditure OR cost utility OR absenteeism OR cost OR economic
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line with the objectives of this review. Four cohorts fulfilled 
PASS after intervention treatment/observational period, while 
4 cohorts (from 15 with available data) fulfilled PASS based 
on a cross-sectional design. 7/14 cohorts with MCID available 
fulfilled the required threshold. Overall, the literature suggests 
that while biologics in combination with MTX alleviate pain, 
many patients with RA continue to experience unacceptable 
levels of pain (Table 3). Data from clinical trials demonstrated 
that MTX in combination with a biologic resulted in greater 
reduction in pain compared with MTX monotherapy [11].
One study confirmed that although treatment with a biologic 
in patients produced clinically meaningful improvements in 
pain, scores remained below the PASS threshold (Table 3) [11]. 
In addition, patients with RA continue to experience moderate 
pain, despite ongoing treatment with DMARDs [12].
Interestingly, patients’ global assessment of disease 
accounted for 32.8 % of the variation in pain intensity and 
10.7 % of the variation in morning stiffness; these out-
comes were considered more important to patients than 
radiographic or clinical outcomes, such as the number of 
tender and swollen joints [13]. Overall, the current litera-
ture suggests that pain persists at an unacceptable level in 
patients with RA.
Physical functioning
In line with the objectives of this review, 27 articles (com-
prising 29 cohorts) on physical functioning were identified. 
Seventeen cohorts fulfilled PASS after intervention treat-
ment/observational period, while 13 cohorts (from 29 with 
available data) fulfilled PASS based on a cross-sectional 
design. 20/29 cohorts with MCID available fulfilled the 
required threshold. Overall, physical functioning out-
comes persist at an unsatisfactory level in patients with RA, 
particularly in those who do not achieve MCID or PASS 
thresholds despite ongoing treatment (Table 3). Remaining 
independent and carrying out activities of daily living are 
paramount to patients with RA; as such, improved mobil-
ity and mitigating pain and fatigue have been identified as 
critical treatment goals [14].
Evidence in the literature suggests that mild to moderate 
disability (mean health assessment questionnaire [HAQ] 
score of 1.2–1.8 at baseline) is above the threshold that 
patients would consider acceptable [15, 16]. Clinical stud-
ies showed that continuing patients on csDMARDs, when 
they may benefit from treatment with biologics, failed to 
result in improved physical functioning [17], highlighting 
the advantages of switching to intensive treatment strate-
gies in patients with an inadequate response to csDMARDs.
Consistent with findings from clinical trials, data from 
observational studies suggested that physical functioning 
scores, captured using patient-reported outcomes (PROs) 
such as the HAQ and the medical outcomes short form-
36 (SF-36), failed to reach PASS thresholds and seldom 
reached clinical targets for minimal residual disease activ-
ity. These shortcomings were observed in patients receiv-
ing csDMARDs and biologics, suggesting that treatment 
goals—from patients’ and physicians’ perspectives—are 
rarely met with existing therapies.
Moreover, current evidence suggested that available 
therapies often fail to improve HAQ scores by clinically 
important margins, with patients frequently experiencing 
an unacceptable level of physical disability despite ongoing 
treatment [18, 19]. Furthermore, approximately 47 % of 
patients failed to achieve HAQ levels indicative of minimal 
residual disease activity (a secondary goal of treatment for 
patients unlikely to achieve remission) [20, 21].
There was no conclusive evidence in the reviewed lit-
erature to determine the effect of available treatments on 
morning stiffness in patients with RA. Overall, physical 
functioning continues to pose a problem for many patients 
with RA, despite ongoing treatment.
Mental functioning
In line with the objectives of this review, 16 articles 
assessed mental functioning in patients with RA, using the 
four domains that comprise the mental component score 
(MCS) or the mental health subdomain of the SF-36. In 
general, suboptimal mental health persists in a substantial 
proportion of patients with RA (Table 3). Studies showed 
Table 2  Established MCID and PASS values across a range of com-
monly utilized outcome measures
HAQ health assessment questionnaire, MCID minimal clinically 
important difference, MCS mental component score, N/A not applica-
ble, PASS patient acceptable symptom state, PCS physical component 
summary, SF-36 medical outcomes short form-36, VAS visual analog 
scale
a The PASS are all reported in a single article [79]





HAQ –0.2 Wells et al. [16] 1.0
SF-36 PCS 2.5 Strand and Singh 
[56]
N/A
Physical function 5.0 50.0
Role-physical 5.0 N/A
Bodily pain 5.0 41.0
General health 5.0 47.0
SF-36 MCS 2.5 N/A
Role-emotional 5.0 N/A
Vitality 5.0 40.0
Social function 5.0 75.0
Mental health 5.0 68.0
Pain (VAS) –11.8 Pope et al. [57] 34.0
Fatigue (VAS) –10.0 Wells et al. [58] 50.0
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that approximately 48–92 % of patients who remained on 
MTX—despite meeting eligibility criteria for treatment 
with biologics—did not meet MCID thresholds [17]. Fur-
thermore, 35–66 % of patients failed to meet MCID thresh-
olds across six clinical trials of biologic treatments [17]. A 
study in a cohort of South African patients with early RA 
concluded that only 43 % of previously DMARD-naïve 
patients individually met the MCID threshold, and 66 % of 
patients had suboptimal mental health (SF-36 MCS < 66.6) 
after 12 months of DMARD therapy [22].
There were no studies that used disease-specific meas-
ures of mental health. Taken together, these findings sug-
gest that there is an unmet mental health need, and failure 
to intensify treatment may result in mental health problems 
persisting in many patients with RA.
Fatigue
Unacceptable levels of fatigue persist in a substantial 
proportion of patients with RA, despite the introduction 
of intensive treatments. Data from clinical trials demon-
strated that biologics, in combination with MTX, often fail 
to produce meaningful improvements in fatigue and that 
patients with an inadequate response to MTX continue 
to experience substantial distress due to fatigue [20, 23]. 
Furthermore, high multidimensional assessment of fatigue 
scores was strongly correlated with disease activity, sug-
gesting that fatigue is severer for patients with moderate 
to severe disease activity, compared with those with LDA 
[24].
Overall, the current literature suggests that fatigue con-
tinues to have a considerable negative impact on more than 
half of patients with RA [9] and is a major determinant 
of QoL [25–27]. The absence of fatigue, although rarely 
achieved, has previously been defined as a key component 
of one of the more stringent definitions of remission in RA 
[28]. Moreover, research has confirmed that 40–80 % of 
patients with RA believe that reducing fatigue should be a 
key treatment aim, although fatigue-related endpoints were 
rarely reported in clinical trials [27, 29, 30].
Social functioning
The impact of RA on social functioning was not the pri-
mary focus for any of the reviewed articles. As such, lim-
ited evidence was available regarding the therapeutic 
potential of available treatments on social functioning in 
patients with RA. However, one study concluded that a 
negative impact on relationships with friends and family 
was reported by approximately one-fifth of patients with 
RA [31].
PASS values for social functioning were met in 1 of 10 
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overall sample who had been receiving MTX at the start of 
the study period [32]. Of note, the PASS value for social 
functioning for patients with RA is much higher than that 
observed for other subdomains of the SF-36, highlight-
ing the importance of maintaining high levels of social 
functioning in patients with RA. Overall, these data dem-
onstrate that acceptable levels of social functioning may 
not be achievable for patients with RA, despite ongoing 
treatment.
Sexual functioning
In patients with RA, sexual disability can manifest due to 
several factors, including joint pain and fatigue, difficulty 
in assuming certain positions when hip or knee movements 
are restricted, and diminished sexual desire [33].
In a 6-month observational study of sexual activity and 
sexual dysfunction in patients with RA receiving treatment 
with biologics or DMARDs, 53.8 % of men and 45.7 % of 
women experienced some form of sexual dysfunction in 
response to a multidimensional patient-reported outcome 
measures questionnaire [34]. One survey revealed 22 % of 
biologic-experienced and 16 % of biologic-naïve patients 
(P ≤ 0.05) experienced problems with sexual function 
[31]. However, these data were collected from one question 
asked as part of a telephone survey, rather than as part of a 
disease-specific PRO, and should therefore be interpreted 
with caution.
Although problems with sexual functioning continue to 
adversely affect patients with RA, data in the current lit-
erature are sparse, highlighting the unmet needs of patients 
with RA.
The role of patients in management decisions 
regarding therapy
Perceived control over RA may be a key component in 
determining patients’ wishes to maintain or switch treat-
ments. However, based on the reviewed literature, it was 
not possible to accurately ascertain how patients gauged 
control of RA.
There was evidence to suggest that patients’ fear of 
side effects was a key barrier to switching treatment and 
that non-adherence was often attributed to side effects 
associated with their current medication [35]. Of note, 
a post-marketing surveillance study concluded that 
patient-reported self-administration of medication led 
to feelings of independence (89.1 %) and improved QoL 
(83.6 %), and may be desirable for many patients with 
RA [36]. Based on the current literature, further research 
is warranted to understand patients’ experiences of RA 
treatment.
Impact on work
The physical and mental effects of RA continue to be a 
challenge for patients with RA and often result in a sub-
stantial negative impact on patients’ ability to work. 
Despite this, efforts to reduce the negative work-related 
impacts of RA are not recognized treatment goals of exist-
ing therapies.
Historically, an estimated one-third of patients with 
RA terminate employment prematurely, and 5 years after 
diagnosis, 30–40 % of patients experience work disabil-
ity [37–40]. Relationships between work disability and 
PROs that are of clinical importance such as HAQ, modi-
fied Health Assessment Questionnaire (mHAQ), and pain 
scores showed that increased severity of pain and physi-
cal disability were associated with greater work disability 
[41–43].
There was evidence in the literature that intensive treat-
ment strategies with a combination of DMARDs may play 
a crucial role in reducing the adverse work-related impacts 
of RA [41, 44]. Reducing work disability in patients with 
RA is crucial as engaging in paid work has a positive effect 
on health-related quality of life (HRQoL) [12]. Novel treat-
ments that adequately address pain and physical function-
ing, mitigating the negative work-related effects of RA, are 
eagerly awaited.
Economic burden as an unmet need in RA at the 
societal level
RA is associated with a large economic burden to individ-
ual patients, their families, and to society, with an estimated 
total annual economic burden of €45.3 billion in Europe 
and €41.6 billion in the USA [45].
Direct costs associated with RA include medications, 
hospitalizations, clinic visits, laboratory monitoring imag-
ing, toxicity, and medical assist devices. Indirect costs, 
such as loss of earnings, caregiver productivity, and intan-
gible costs arising from pain, depression and anxiety, and 
suboptimal QoL also contribute to the economic burden 
of RA [46]. Of note, overall costs were greater for those 
treated with multiple versus single TNF-α inhibitors: 
($8340 vs. $7058), as were RA-related healthcare costs 
($15,048 vs. $13,312) and total healthcare costs ($26,679 
vs. $21,831) [47]. Studies of indirect costs generally 
focus on absenteeism associated with the disease, and 
there was limited research on presenteeism or productiv-
ity impairments to caregivers, both of which may present 
a substantial economic strain. While economic factors 
are an important element in determining patient access to 
new treatments, drug approval processes and reimburse-
ment decisions based on Health Technology Assessments, 
692 Rheumatol Int (2016) 36:685–695
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coupled with access to specialist care, strongly influence 
patient access to current treatments for RA [48].
It is well documented that costs increase with disease 
duration, severity, and activity of disease, and achieving 
remission or LDA through early intervention with effi-
cacious therapies could confer notable cost savings and 
thereby ease the economic burden of RA.
Discussion
Despite the wide array of available treatments for RA, 
clinical and patients’ needs remain unmet across key 
domains such as pain, physical function, mental function, 
and fatigue, which can all adversely affect social function, 
sexual function, the ability to work, and overall well-being.
The expansion in the pharmacotherapeutic armamentar-
ium witnessed in the last decade and a half since the advent 
of the biologic era has hugely improved the achievable out-
comes for patients with respect to improvement in symp-
toms and signs, prevention of structural damage, and pres-
ervation of functional status. But despite these advances, 
significant unmet needs remain as listed above and iden-
tified in this review of note, in distinction to past genera-
tions of patients with RA where joint deformity and conse-
quent disability were very evident to the treating physician, 
many areas of contemporary unmet need are of a subjective 
nature and known only to the patient themselves such as 
fatigue, pain, and mental function. It is therefore important 
that the treating physician recognizes this, and having iden-
tified the issues that concern an individual patient, address 
them where possible with both pharmacological and non-
pharmacological interventions as appropriate.
It is well documented that patients want to feel engaged 
and empowered in their treatment, with aspirations that 
focus on, but are not limited to, reduction in pain, joint 
swelling, and general well-being. However, reduction in 
inflammation, prevention of structural damage and inca-
pacity, and achieving remission are regarded by physi-
cians as key treatment goals [31, 49–51]. A recent patient 
focus group reported that, according to a holistic approach 
to RA management, pharmacotherapy is an important but 
not the sole element, in determining clinical outcomes [52]. 
Indeed, the Assessment of Spondylo Arthritis international 
Society (ASAS)/European League Against Rheumatism 
(EULAR) recommendations have a prominent emphasis 
on body functions and structures, whereas patient-centered 
care requires non-pharmacological and psychosocial strate-
gies to complement the effects of therapeutic agents [53]. 
In this regard, the patient focus group emphasized the 
importance of a multidisciplinary approach that may be 
instrumental in optimizing the treatment of RA, facilitating 
improved patient education and dialog between patients 
and physicians [54].
A recent questionnaire, which included multiple choice, 
multiple response, and open-ended questions, showed that 
one-third of respondents reported that they always or usu-
ally experienced symptoms of RA that their rheumatolo-
gists do not believe or understand, possibly indicative of 
poor physician–patient communications and/or shortcom-
ings in education. Moreover, the majority of respondents 
stated that additional medications were needed beyond dis-
ease treatment to help control the remaining symptoms of 
RA, with only 8 % of respondents stating that their symp-
toms were completely relieved by DMARD or biologic 
therapy [55].
This literature review revealed that a substantial pro-
portion of patients with RA believe that the core symp-
toms remain inadequately addressed. The literature con-
sistently supports intensive treatment strategies, with 
combination DMARDs or combinations of DMARDs 
and biologics providing more effective control of RA 
compared with monotherapy or continuation with csD-
MARDs. These findings were echoed in the economic 
data, highlighting the overall cost benefits of an effective, 
intensive therapy. Taken together, data assessed in this 
review highlight the need for alternative, novel agents that 
address the multifactorial nature of RA, and ultimately 
bridge the gap between patients’ and physicians’ treat-
ment goals and aspirations.
Conclusions
Despite advances in treatment that have helped to improve 
outcomes for patients with RA, treatment goals, aspira-
tions, and expectations are seldom met for both patients 
and physicians. RA continues to present a considerable 
human and economic burden. Novel treatment approaches 
for RA need to be tested for their ability to ameliorate con-
temporary unmet need.
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